Qualigen Therapeutics Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| QLGN | -86.88% | -98% | ||
| S&P | -17.06% | +41.99% | +7.26% | +28% |
Qualigen Therapeutics Company Info
Financial Health
General
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Revenue | $1.44M | +24.8% |
| Gross Profit | $0.16M | +0.7% |
| Gross Margin | 11.3% | -19.3% |
| Market Cap | $11.24M | -70.3% |
| Market Cap / Employee | – | – |
| Employees | – | – |
| Net Income | -$4.06M | +41.9% |
| EBITDA | -$4.29M | -9.2% |
Assets
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $6.62M | -46.3% |
| Accounts Receivable | $0.60M | -4.8% |
| Inventory | 1.481524 | +25.8% |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $1.37M | +5,363.4% |
| Short Term Debt | $1.14M | +308.6% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -93.1% | – |
| Return On Invested Capital | -98.8% | -75.1% |
Cash Flow
QUARTERLY ANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$3.15M | +5.9% |
| Operating Free Cash Flow | -$3.14M | +5.9% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 2.28 | 1.72 | 1.53 | 0.93 | -73.5% |
| Price to Sales | 5.81 | 5.20 | 4.36 | 2.08 | – |
| Price to Tangible Book Value | 29.17 | 17.99 | 15.06 | 27.85 | -10.5% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -3.72 | -2.30 | -4.37 | -2.37 | -56.4% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | – | -124.7% | -129.9% | -159.4% | – |
| Total Debt | $1.68M | $1.64M | $2.54M | $2.51M | +724.3% |
